Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a patient with colon cancer and a history of autoimmunity, skin and gastrointestinal toxicity developed after the receipt of pembrolizumab. Interleukin-17 blockade reversed the autoimmunity but led to tumor progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“suggesting that IL-17 may have anti-tumor effects”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Esfahani and Miller, 2017
In the citing paper
“A recent case report (Esfahani and Miller, 2017) describes a male patient with metastatic colon cancer who experienced severe flare of previously mild psoriasis following treatment with pembrolizumab (Anti-PD1).”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Esfahani and Miller, 2017
In the citing paper
“However, there are exceptions, indicating that better understanding of the interplay between the developing antitumor response following ICI therapy and the use of immunosuppressive agents is needed (117, 122, 123).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [122]
In the citing paper
“Notably, IL-17 blockade and its probable implications in promoting tumor growth and metastasis have been reported in the literature.100,101”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [101]
In the citing paper
“In this patient, several other inflammatory cytokines, mainly IL-6, TNF-α and IL-17A, were also elevated during the rejection phase, and were likely promoting the observed concomitant skin and gastrointestinal toxicities29–31.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [31]
Citations
Cites
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 813
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
TH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
Endogenous IL-17 contributes to reduced tumor growth and metastasis
Kryczek, I., Wei, S., Szeliga, W., Vatan, L., & Zou, W. (2009) · Blood · doi:10.1182/blood-2008-09-177360 · Cited by 403
Human T H 17 Cells Are Long-Lived Effector Memory Cells
Kryczek, I., Zhao, E., Liu, Y., Wang, Y., Vatan, L., Szeliga, W., Moyer, J., Klimczak, A., Lange, A., & Zou, W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002949 · Cited by 278
Cited by
Items 101–200 of 200
Miao, Y., Quan, W., Tang, X., Shi, W., Li, Q., Li, R. J., Wang, J., Gan, J., Dong, X., Liang, H., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.89376 · Cited by 23
Pach, J. J., Valido, K., Belzer, A., & Leventhal, J. S. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00866-z · Cited by 21
Wu, C., Li, Z., Wu, Q., Lin, S., & Xie, X. (2021) · Immunotherapy · doi:10.2217/imt-2020-0230 · Cited by 21
Sebastiani, G. D., Scirocco, C., & Galeazzi, M. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.06.005 · Cited by 23
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity
Mazzarella, L., Giugliano, S., D’Amico, P., Belli, C., Duso, B. A., Rescigno, M., & Curigliano, G. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.006 · Cited by 21
Prevention and management of cutaneous immune‐related adverse events: EADV Task Force statement
Fattore, D., Apalla, Z., Freites‐Martínez, A., Tommasino, N., Nikolaou, V. A., Lauletta, G., Ortiz‐Brugués, A., Sollena, P., Starace, M. V. R., Gomes, N. P., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70149 · Cited by 20
“44,64,65 Once symptoms are managed, biological treatment can be tapered.”
Chan, K. K., & Bass, A. R. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s282600 · Cited by 29
“Although there are a number of case reports in which anti-IL17 was used to treat ICI-induced psoriasis, in one instance the tumor response was subsequently lost.(86) Anti-IL12/IL23 (ustekinumab) was reported to be effective in two cases of refractory ICI-colitis but has not been used for ICI-arthritis.”
ResultPopa, L. G., Giurcăneanu, C., Portelli, M. G., Mihai, M. M., Beiu, C., Orzan, O. A., Ion, A., & Anghel, T. (2024) · Medicina · doi:10.3390/medicina60030373 · Cited by 19
Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers
Segovia, M., Russo, S., Girotti, M. R., Rabinovich, G. A., & Hill, M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13433 · Cited by 20
Sanchez, K. G., Page, D. B., & Urba, W. J. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.009 · Cited by 21
Vangilbergen, M., Stockman, A., Velde, A. V. D., Garmyn, M., Punie, K., & Hillary, T. (2024) · JAAD International · doi:10.1016/j.jdin.2024.06.006 · Cited by 17
“54”
Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies
Seervai, R. N. H., Sinha, A., & Kulkarni, R. P. (2022) · Clinical and Experimental Dermatology · doi:10.1111/ced.15332 · Cited by 18
Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance
Papp, K. A., Puig, L., Beecker, J. R., Chandran, V., Claveau, J., Cortés, J., Dutz, J. P., Hornick, N. I., Juergens, R. A., Melosky, B. L., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20809 · Cited by 18
“98 A causal relationship was not established.”
McGonagle, D., Bragazzi, N. L., Amital, H., & Watad, . (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102456 · Cited by 14
“17A with rapid recrudescence of the tumours in the face of resolution of the psoriasis and PsA (35).”
BackgroundInfluentialImmune checkpoint inhibitor-induced inflammatory arthritis: identification and management
Williams, S. G., Mollaeian, A., Katz, J. D., & Gupta, S. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1804362 · Cited by 14
Toxicities of Immunotherapy for Small Cell Lung Cancer
Fu, Y., Zheng, Y., Wang, P., & Ding, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.603658 · Cited by 15
Systemic Treatment of Cutaneous Adverse Events after Immune Checkpoint Inhibitor Therapy: A Review
Brown, A. M., Masterson, W. M., Lo, J., & Patel, A. B. (2023) · Dermatitis · doi:10.1097/der.0000000000000776 · Cited by 17
“23 However, many biologic agents, such as omalizumab, have not demonstrated an increased riskofmalignancy to date.”
Drug eruptions with novel targeted therapies – immune checkpoint and EGFR inhibitors
Pospischil, I., & Hoetzenecker, W. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14641 · Cited by 15
Lung Cancer Heterogeneity in Modulation of Th17/IL17A Responses
Armstrong, D., Chang, C.-Y., Lazarus, D. R., Corry, D. B., & Kheradmand, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01384 · Cited by 15
“Another case showed that anti-PD-1 treatment in patients with melanoma increased Th17 cell numbers in responders compared to non-responders (43).”
BackgroundInfluentialGrice, S., Olsson-Brown, A. C., Naisbitt, D. J., & Hammond, S. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.4c00067 · Cited by 14
Seervai, R. N. H., Heberton, M. M., Cho, W. C., Gill, P., Murphy, M. B., Aung, P. P., Nagarajan, P., Torres-Cabala, C. A., Patel, A. B., Bañobre, J. R., et al. (2021) · Journal of Cutaneous Pathology · doi:10.1111/cup.14185 · Cited by 13
“The anti-IL-17A antibody secukinumab is efficacious in managing pustular psoriasis(45) and has been used in severe cases of ICI-mediated psoriasiform irAE with or without a negative impact on antitumor response.(16,43,44) Our patient was treated with the IL-12/IL-23 inhibitor ustekinumab, also shown to be effective in…”
Gonzalez-Mazón, I., Sánchez-Bilbao, L., Martín-Varillas, J. L., García‐Castaño, A., Ruiz, M. D., Piña, I. B., Hernández, J. L., Castañeda, S., Llorca, J., González-Gay, M. Á., et al. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/o5nvgv · Cited by 16
Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and TumorPreprint
Blum, S. M., Zlotoff, D. A., Smith, N. P., Kernin, I., Ramesh, S., Zubiri, L., Caplin, J., Samanta, N., Martin, S., Tirard, A. J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557794 · Cited by 13
Rheumatologic immune checkpoint inhibitor-related adverse events
DeFoe, M., & Bermas, B. L. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000935 · Cited by 14
“However, one case report showed loss of tumor response after secukinumab therapy [53]; leading EULAR to recommend preferentialuseofTNF-alpha inhibitors or tocilizumabover other biologics at time for the management of ICIassociated inflammatory arthritis [40 && ].”
BackgroundLi, Y. J., Msaouel, P., Campbell, M. T., Hwu, P., Diab, A. K., & Kim, S. T. (2024) · RMD Open · doi:10.1136/rmdopen-2024-004308 · Cited by 13
“18 Taken together, clinical, translational and basic research are required to identify risk factors associated with the attenuation of ICI anti-tumour efficacy due to IL-23/17 inhibition.”
BackgroundA Unique Role of T Helper 17 Cells in Different Treatment Stages of Multiple Myeloma
Ma, T., Zhang, Y., Zhou, X., Xie, P., & Li, J. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.12.009 · Cited by 13
Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis
Kišš, I., Kuhn, M., Hrušák, K., Buchler, B., Boublíková, L., & Büchler, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.946307 · Cited by 12
Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis
Takeda, K., & Yanagitani, N. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2022-222628 · Cited by 12
Tison, A., Escoda, T., Kostine, M., Cornec, D., & Chiche, L. (2025) · Joint Bone Spine · doi:10.1016/j.jbspin.2025.105938 · Cited by 14
Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Singh, N., Shahane, A., Sparks, J. A., Bitoun, S., & Cappelli, L. C. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.02.002 · Cited by 12
Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study
Zheng, X., Tao, G., Sun, S. M., Jin, X., Chen, Y., Zhang, Y., Sun, J., & Huang, P. C. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-6899 · Cited by 12
“Mechanisms of tr-AEs caused by PD-1 inhibitors have not been fully elucidated, but it is known that tr-AEs may result from some combination of autoreactive T cells, autoantibodies, and proinflammatory cytokines (45,46).”
BackgroundMadan, V., Ortiz‐López, L. I., Sakunchotpanit, G., Chen, R., Nayudu, K., & Nambudiri, V. E. (2024) · Dermatology and Therapy · doi:10.1007/s13555-024-01198-w · Cited by 10
“How‑ ever, secukinumab may result in a loss of anti‑ tumoral efficacy in patients receiving immuno‑ therapy treatment [64].”
BackgroundZeng, L., Ma, G., Chen, K., & Zhou, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1242336 · Cited by 12
Gu, S. L., Nath, S. S., & Markova, A. (2023) · Pharmaceuticals · doi:10.3390/ph16111610 · Cited by 10
“Among them, one patient experienced tumor progression following secukinumab treatment, while others were treated successfully without cancer progression [173,186,187].”
BackgroundCo Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
Robles, V., Martínez‐Valle, F., & Borruel, N. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906098 · Cited by 12
“As an example, there is evidence that an anti-IL 17 antibody, secukinumab, can impair the effect of pembrolizumab in colon rectal cancer (4), or the deleterious effect on the oncological outcome in retrospective studies of DMARDs in patients with immune-related arthritis (5, 6).”
BackgroundUnderstanding Immune Tolerance of Cancer: Re‐Purposing Insights from Fetal Allografts and Microbes
Barnet, M. B., Blinman, P. L., Cooper, W. A., Boyer, M. J., Kao, S., & Goodnow, C. C. (2018) · BioEssays · doi:10.1002/bies.201800050 · Cited by 11
Lo, J., Heberton, M. M., Pacha, O., Huen, A., & Patel, A. B. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06548-4 · Cited by 15
“There exist few studies that look at safety profiles in biologics use in relation to tumor response, although one study points toward the safety of B-cell depletion in the context of rituximab use [13] and another reported a case of tumor progression after initiation of an IL-17 inhibitor [14].”
BackgroundResultSecukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
Gambardella, A. (2019) · Case Reports in Dermatology · doi:10.1159/000501993 · Cited by 9
Immune Checkpoint Inhibitor-Induced Psoriasis
Pach, J. J., Mbonu, N., Bhullar, S., Cohen, J. M., & Leventhal, J. S. (2024) · Dermatologic Clinics · doi:10.1016/j.det.2024.02.012 · Cited by 8
Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
Kuo, J., Davis, A. D., Rodríguez, E. A., Vela, M. F., Heigh, R. I., Salomao, M. A., & Gurudu, S. (2018) · Case Reports in Gastroenterology · doi:10.1159/000493183 · Cited by 8
Wako, S., Ikeguchi, R., Toda, K., Kobayashi, M., Miyata, R., Kuramochi, H., Ichihara, A., Shimizu, Y., & Kitagawa, K. (2022) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2022.578010 · Cited by 8
Steroid-sparing strategies for managing immune-related adverse events
Huang, J. J., Yousefiasl, M., Singh, N., Grivas, P. D., & Bhatia, S. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013776 · Cited by 8
“69 70 Interestingly, a recent study showed that increased IL-17A expression on CD4+T cells was associated with the onset of irAEs.”
Denaro, N., Nazzaro, G., Murgia, G., Scarfì, F., Cauchi, C., Carrera, C. G., Cattaneo, A., Solinas, C., Scartozzi, M., Marzano, A. V., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417540 · Cited by 7
“Numerous other experiences have supported and confirmed this evidence reported [33,56,58,59,63].”
BackgroundResultChan, K. K., & Bass, A. R. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.02.007 · Cited by 9
Farina, N., Tomelleri, A., Boffini, N., Cariddi, A., Calvisi, S. L., Baldissera, E. M., Matucci‐Cerinic, M., & Dagna, L. (2024) · Rheumatology International · doi:10.1007/s00296-024-05571-y · Cited by 7
“In those patients, no progression of the active cancer was noted [10, 11], although another work had previously hinted at a possible deleterious oncological effect linked to IL-17 inhibition when treating immune-related adverse events to immune checkpoint inhibitors [14].”
Tumor location as a risk factor for severe immune-related adverse events
Blum, S. M., Ouyang, B., Zubiri, L., Leonard, D., Slowikowski, K., Wang, M., Grealish, K., Hathaway, N., Molina, G. E., Shah, N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011312 · Cited by 8
Pourhassan, H., Tryon, D. N., Schaeffer, B. T., Mirshahidi, H., & Wong, J. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0140-2 · Cited by 7
Knochelmann, H. M., Ware, M. B., Rali, A. S., Linderman, S. L., Shantha, J. G., Lawson, D. H., Yushak, M. L., Swerlick, R. A., Paulos, C. M., Yeh, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836845 · Cited by 7
“Indeed, in a patient with colorectal cancer, IL-17 blockade was given to ameliorate toxicity induced by PD-1 therapy; unfortunately, this intervention eventually led to tumor recurrence (25).”
BackgroundKobæk-Larsen, M., Deding, U., Al‐Najami, I., Clausen, B. H., & Christensen, L. P. (2023) · Nutrients · doi:10.3390/nu15235002 · Cited by 7
“In one case report, anti-IL-17A treatment was beneficial for preventing the development of an autoimmune disease in a patient, but at the same time, it caused the loss of an antitumor response in the same patient who also suffered from CRC [54].”
BackgroundLiao, R., Hsu, J. Y., Aboelella, N. S., McKeever, J. A., Thomas-Toth, A. T., Koh, A. S., & LaBelle, J. L. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0344 · Cited by 8
Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité
Kostine, M., Marabelle, A., Schaeverbeke, T., & Kfoury, M. (2019) · médecine/sciences · doi:10.1051/medsci/2019191 · Cited by 12
Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells
Thomson, A., Bento, D. F. C., Scurr, M. J., Smart, K., Somerville, M. S., Keita, Å. V., Gallimore, A., & Godkin, A. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01283-3 · Cited by 6
“This study also highlights the possibility for detrimental clinical outcomes when using IL-17/ TH17-targeted treatments; indeed it has been suggested that clinical response to anti-PD-1 may be reliant on TH17 responses and treatment success is compromised by IL-17A blockade.(6,10,11) We have previously shown an advers…”
Rheumatic complications of checkpoint inhibitors: Lessons from autoimmunity
Reynolds, G. (2023) · Immunological Reviews · doi:10.1111/imr.13242 · Cited by 14
Cogrossi, L. L., Policastro, A., Zordan, P., Grioni, M., Tosi, A., RIZZO, N., Mattorre, B., Lorenzoni, M., Meregalli, G., Sisti, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65312-y · Cited by 8
“IL-17 is involved in several IrAEs 52 , ICB may unleash commensal-speci fi c Th17 responses leading to skin toxicity 14 , and IL-17 blockade reversed psoriatic rash in one patient treated with pembrolizumab 53 .”
Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade:
Curry, J. L., Chon, S. Y., Marques-Piubelli, M. L., & Chu, E. Y. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.01.002 · Cited by 6
Tislelizumab-related enteritis successfully treated with adalimumab: A case report
Chen, N., Qian, M.-J., Zhang, R.-H., Gao, Q., He, C.-C., Yao, Y., Zhou, J., & Zhou, H. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i28.10186 · Cited by 5
Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity
Silva-Pilipich, N., Covo-Vergara, Á., Vanrell, L., & Smerdou, C. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.05.006 · Cited by 5
Benesova, K., & Leipe, J. (2020) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-020-00825-z · Cited by 5
Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient
Ke, J., Guo, M., Zhao, X., Liu, N., Meng, Q., & Deng, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573495 · Cited by 4
“The incidence of cutaneous immune-related adverse events (ciRAEs) in patients receiving ICT has been reported to range from 20% to 40% (4).”
InfluentialGreene, A., Penner, S., Edmond, A., Camou, M., Niu, J., & Abbott, J. K. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241269712 · Cited by 4
“11 As shown in Table 1 including our case, fi ve of the six cases were reported in the setting of pembrolizumab (PD-1 inhibitor), while one case was reported secondary to atezolizumab (PD-L1 inhibitor).”
Tingry, T., Massy, E., Piperno, M., Auroux, M., Kostine, M., Maillet, D., Amini‐Adlé, M., Fabien, N., Estublier, C., Gonçalves, D., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.01.016 · Cited by 4
Xia, J., Wen, Y., Xiao, M., Ye, D., Gao, Y., Tang, D., Zhang, X., Chen, J., Li, Q., & Yao, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1391698 · Cited by 4
Reply to ‘Personalized treatment of immune-related adverse events — balance is required’
Esfahani, K., & Calabrese, L. H. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0401-3 · Cited by 4
Self-citationEsfahani, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0480-1 · Cited by 3
“In support of this hypothesis, we previously reported a case of irEC and psoriasis successfully treated with an IL-17 antagonist but with the ultimate end-result of reversal of the anti-tumor efficacy from checkpoint inhibitors [5].”
Self-citationMarques-Piubelli, M. L., Navarrete, J., Ledesma, D. A., Hudgens, C. W., Lazcano, R., Alani, A., Huen, A., Duvic, M. A., Nagarajan, P., Aung, P. P., et al. (2024) · Cells · doi:10.3390/cells13050419 · Cited by 3
Rios, A. A., Salazar, G. T., Zhang, N., & An, Z. (2019) · Antibody Therapeutics · doi:10.1093/abt/tbz003 · Cited by 3
“Most recently, targeted mediators of specific immune responses such as secukinumab, an IL-17A cytokine inhibitor, have been successfully employed in cases where irAEs were severe enough to require combination therapy [21, 22].”
BackgroundSkin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies
Tran, H. T. T., Tran, T. M., Le, D. V., Jacobs, J. C., Nguyen, T. M., Trinh, H. L., Vo, B. T., Tran, T. S., & Nguyen, G. H. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01333-5 · Cited by 6
Georgy, D., Sedeek, H. N., Abaza, N. E., Eldeeb, S. E. K., Khamis, S. M., Elgamil, M. R., & Magar, R. W. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102564 · Cited by 7
Calabrese, L. H., & Calabrese, C. M. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000684 · Cited by 3
“A single case report of clear efficacy of secukinumab in a patient with both colitis and psoriasis irAEs who initially responded to anti-PD-1 showed subsequent tumor progression [51].”
BackgroundPospischil, I., & Hoetzenecker, W. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14641_g · Cited by 2
Management of refractory checkpoint inhibitor-induced colitis
Zaher, A., Santos, M. J. M. N., Elsaygh, H., Peterson, S. J., Cruz, C. C., Thomas, A. S., & Wang, Y.-H. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2496431 · Cited by 1
“Secukinumab is an IL-17 inhibitor with subcutaneous administration that has demonstrated clinical improvement of IMDC as first-line therapy in one case report that described a patient experiencing both skin and gastrointestinal irAEs induced by pembrolizumab [63].”
Shao, S., Zheng, W., Li, X., Qi, A., Gu, Y., Gong, Y., Wang, Q., Jiao, L., & Xu, L. (2025) · Cancer Management and Research · doi:10.2147/cmar.s528555 · Cited by 1
Precision toxicity control in checkpoint immunotherapy
Sun, Z., Yang, X., Shen, W., Li, Z., Guan, M., Deng, X., & Jin, H. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.09.005 · Cited by 1
Association of SIRT6 Expression With Risk of Pneumonitis Induced by Radiotherapy in Cancer Patients
Yu, F., Gong, Z., Li, Y., Naseem, D. F., Li, C., Wen, M., Zhao, B., Xu, Z., Zhang, S., Zang, R., et al. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23900 · Cited by 2
“Studies have indicated that activated T lymphocytes may contribute to the production of pro ‐ inflammatory cytokines such as IFN ‐ γ and IL ‐ 17 [67 – 69].”
Han, Y., Mora, J., Putyrski, M., Huard, A., da Silva, P., Scholz, A., Elwakeel, E., Lang, G.-P., Scholz, T., Schmid, T., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3213912 · Cited by 1
Medina, F. J. N., Segura, B. T., Rodríguez, E. G., García, S. M., Díaz, B. R., & Rodríguez‐Abreu, D. (2020) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.08.011
Nebenwirkungen immunonkologischer Therapien
Benesova, K., & Leipe, J. (2020) · Aktuelle Rheumatologie · doi:10.1055/a-1209-0659
“Die Therapie mit Interleukin17Inhibitor Secukinumab war in einem Fall mit Arthr algien, Psoriasis und Colitis als irAE mit einem Tumorprogress as soziiert und wird seither zurückhaltend bei irAEs verwendet [11, 39].”
Circulating Biomarkers of Immunotherapy Response and Immune-Related Events
Sierra-Davidson, K. (2020) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Medina, F. J. N., Segura, B. T., Rodríguez, E. G., García, S. M., Díaz, B. R., & Rodríguez‐Abreu, D. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.08.008
Diagnostik und Management rheumatischer "immune-related adverse events"
Benesova, K., & Leipe, J. (2021) · Orthopädie & Rheuma · doi:10.1007/s15002-021-3328-x
(2017) · Reactions Weekly · doi:10.1007/s40278-017-33925-9
Pulmonary Side Effects of Immunotherapy
Erol, C., & Şendur, M. A. N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_349-1
Autoimmune Phenomena in Cancer Patients Treated with Immune Checkpoint Inhibitors
Tocut, M., Ehrenfeld, M., & Zandman‐Goddard, G. (2024) · Wiley eBooks · doi:10.1002/9781119858430.ch18
Cogrossi, L. L., Zordan, P., Grioni, M., Tosi, A., RIZZO, N., Policastro, A., Mattorre, B., Lorenzoni, M., Meregalli, G., Sisti, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.08.590282
“IL-17 is involved in several IrAEs 62 , ICB may unleash commensal-specific Th17 responses leading to skin toxicity 23 , and IL-17 blockade reversed psoriatic rash in one patient treated with pembrolizumab 63 .”
BackgroundEvidence That Circulating T Cells at Treatment Onset Predict Response to PD-1 Inhibitors
Salamaliki, C., Pouliasi, F., Liolis, E., Verigou, E., Koutras, A. K., Makatsoris, T., Kalofonos, C. P., Liossis, S. C., & Solomou, E. E. (2024) · Annals of Case Reports · doi:10.29011/2574-7754.101788
Nephrological and Rheumatic Complications of Checkpoint Inhibitors
Fenoglio, R., Roccatello, D., Barreca, A., Simone, E. D., & Sciascia, S. (2024) · Rare diseases of the immune system · doi:10.1007/978-3-031-60855-1_13
The Immunoradiotherapy in Nasopharyngeal Carcinoma
Miao, J., Xiang, C., & Liu, C. (2025) · Springer eBooks · doi:10.1007/978-981-96-3659-4_6
Adverse reactions of immune checkpoint inhibitors
Рафилевна, З. Э., Kaliberdenko, V. B., Рустамовна, К. Э., Beter, V. S., Pronkina, T. V., Kushner, V. A., & Taran, V. V. (2025) · Medical Immunology (Russia) · doi:10.15789/1563-0625-aro-3191
Hadfield, M. J., Merkin, R. D., Rouhani, S. J., & Reynolds, K. L. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101648
Pulmonary Side Effects of Immunotherapy
Erol, C., & Şendur, M. A. N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00775-9_349
Feng, W.-Q., Zhang, Y., Xu, Z.-Q., Yu, S., Huo, J.-T., Tuersun, A., Zheng, M.-H., Zhao, J., 宗雅萍, & Lu, A. (2024) · Figshare · doi:10.6084/m9.figshare.26590706
Feng, W.-Q., Zhang, Y., Xu, Z.-Q., Yu, S., Huo, J.-T., Tuersun, A., Zheng, M.-H., Zhao, J.-K., 宗雅萍, & Lu, A. (2024) · Figshare · doi:10.6084/m9.figshare.26590703
Manifestations rhumatologiques des traitements du cancer et leur prise en charge
Tison, A., Bitoun, S., Escoda, T., & Chiche, L. (2026) · Revue du Rhumatisme · doi:10.1016/j.rhum.2025.12.021
Immune checkpoint inhibitor-induced joint involvement
Quelain, J., Henry, J., Belkhir, R., Mariette, X., & Bitoun, S. (2026) · La Presse Médicale · doi:10.1016/j.lpm.2026.104340
Moura, M. J., Chatterjee, A., Wali, S., Garza, D. M., Salim, H., Rong, J., Menon, R., Jafri, F. I., Rivera, A. C. U., Mortan, R. E., et al. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2659253 · Cited by 1
“Agents such as secukinu-mab (an IL-17 inhibitor) have been reported in isolated cases but are used cautiously because of their potential to worsen underlying inflammatory bowel disease [48].”
Immune-mediated Arthritis after Treatment with Nivolumab in a Patient with Malignant Melanoma
Ivanova, I. (2026) · Rheumatology (Bulgaria) · doi:10.35465/szed3p23
Li, H. L., Charmsaz, S., Kao, C., Pazzi, C., Brancati, M., Leatherman, J. M., Zhao, X., Arif, W., Lee, R. P., Hernandez, J. P., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-1611
Guselkumab for checkpoint inhibitor-exacerbated psoriasis in a patient with metastatic melanoma
Conlon, O., Herlihy, M., Safta, Y., Goh, Y., Reilly, A., Murphy, A., & O’Kane, M. (2026) · Clinical and Experimental Dermatology · doi:10.1093/ced/llag280
Tsuruta, Y., Mier-Aguilar, C. A., Bae, S., Yusuf, N., & Xu, H. (2026) · Biomedicines · doi:10.3390/biomedicines14081746
Metadata
- Authors
- Esfahani, K., & Miller, W. H.
- Affiliations
- McGill University (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-05-18
- Volume
- 376
- Issue
- 20
- Pages
- 1989-1991
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2615312978
- Cited by
- 200
- References
- 5
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 27 · 2023: 22 · 2022: 14 · 2021: 30 · 2020: 33 · 2019: 28 · 2018: 15 · 2017: 3
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pembrolizumab, immune checkpoint inhibitor toxicity, autoimmune toxicity, colon cancer, tumor progression, immune-related adverse events
- MeSH terms
- Antibodies, Monoclonal, Autoimmune Diseases, Colonic Neoplasms, Crohn Disease, Exanthema, Humans, Male, Middle Aged, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.